### Anti-Human CD105 Antibody, Clone 43A3, FITC

## **Antibodies**

Mouse monoclonal IgG1 antibody against human, mouse CD105 (endoglin), FITC-conjugated

Catalog #60039FI #60039FI.1 100 Tests 5 µL/test 25 Tests 5 µL/test



Scientists Helping Scientists™ | www.stemcell.com

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713 INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

## **Product Description**

The 43A3 antibody reacts with CD105 (endoglin), an ~180 kDa cell surface glycoprotein which is a disulfide-bonded homodimer of ~90 kDa type I transmembrane subunits. CD105 is a component of the TGF-\$\beta\$ receptor complex and is expressed by vascular endothelial smooth muscle cells, syncytiotrophoblasts of placenta and activated macrophages, and at relatively low levels by stromal fibroblasts. Its expression is also observed in some types of tumors, and levels are up-regulated on the endothelium during angiogenesis. In concert with signaling receptors, CD105 binds to TGF-β1 and TGF-β3 with high affinity, but does not bind TGF-β2. Other ligands reportedly include Activin A, BMP-2, and BMP-7. CD105 has important roles in angiogenesis, cardiovascular development, and vascular remodeling, and the protein serves a regulatory role in cytoskeletal reorganization by modulating the sites of focal adhesion and cellular migration. Certain mutations in CD105 result in the autosomal dominant disorder hereditary hemorrhagic telangiectasia.

Target Antigen Name: CD105 (Endoglin)

Alternative Names: Endoglin Gene ID: 2022

Species Reactivity: Human, Mouse

**Host Species:** Mouse Clonality: Monoclonal Clone: 43A3

Isotype: IgG1, kappa

Immunogen: L-cells transfected with human CD105 Conjugate: FITC (Fluorescein isothiocyanate)

# **Applications**

Verified: FC Reported: FC

Special Applications: This antibody clone has been verified for labeling human mesenchymal cells grown in MesenCult™

Proliferation Kit (Human; Catalog #05411).

Abbreviations: CellSep: Cell separation; ChIP: Chromatin immunoprecipitation; FA: Functional assay; FACS: Fluorescence-activated cell sorting; FC: Flow cytometry; ICC: Immunocytochemistry; IF: Immunofluorescence microscopy; IHC: Immunohistochemistry; IP: Immunoprecipitation; RIA: Radioimmunoassay; WB: Western blotting

# **Properties**

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) bovine serum albumin Purification:

The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The

solution is free of unconjugated FITC.

Stability and Storage: Product stable at 2 - 8°C when stored undiluted. Do not freeze. Protect product from prolonged exposure to

light. For product expiry date, please contact techsupport@stemcell.com.

Directions for Use: For flow cytometry, the suggested use of this antibody is ≤ 5 µL per 1 x 10^6 cells in 100 µL. It is

recommended that the antibody be titrated for optimal performance for each application.


Page 1 of 2

#### Anti-Human CD105 Antibody, Clone 43A3, FITC

## **Antibodies**



## Data



Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs) cultured for 24 hours with or without lipopolysaccharide (LPS) and labeled with Anti-Human CD105 Antibody, Clone 43A3, FITC. Histograms show labeling of PBMCs cultured in the absence (Unstimulated) or presence (Stimulated) of LPS. Labeling of LPS-stimulated PBMCs with a mouse IgG1, kappa isotype control antibody, FITC is shown (solid line histogram).

### Related Products

For a complete list of antibodies, including other conjugates, sizes and clones, as well as related products available from STEMCELL Technologies, visit www.stemcell.com/antibodies or contact us at techsupport@stemcell.com.

### References

- 1. Grau-Vorster M et al. (2019) HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: A two-site study. Stem Cell Res Ther 10(1): 1–8. (FC)
- 2. Crippa S et al. (2019) Bone marrow stromal cells from β-thalassemia patients have impaired hematopoietic supportive capacity. J Clin Invest 129(4): 1566–80. (FC)
- 3. Nishi H et al. (2017) Neutrophil Fc g RIIA promotes IgG-mediated glomerular neutrophil capture via Abl / Src kinases. J Clin Invest. 127(10): 3810–26. (FA, Adhesion assay)
- 4. Bonnaure G et al. (2016) Bone marrow mesenchymal stem cells enhance the differentiation of human switched memory B lymphocytes into plasma cells in serum-free medium. J Immunol Res 2016. (FC)
- 5. O'Carroll SJ et al. (2015) Pro-inflammatory TNFa and IL-1ß differentially regulate the inflammatory phenotype of brain microvascular endothelial cells. J Neuroinflammation 12(1): 1–18. (FC)
- 6. Brandau S et al. (2014) Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS One 9(9): e106903. (FC) 7. Akiyama K et al. (2012) Characterization of bone marrow derived mesenchymal stem cells in suspension. Stem Cell Res Ther 3(5): 40. (WB)
- 8. Marolt D et al. (2012) Engineering bone tissue from human embryonic stem cells. Proc Natl Acad Sci USA 109(22): 8705–9. (FC)
- 9. Honmou O et al. (2011) Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 134(6): 1790–807.
- 10. Osaka M et al. (2010) Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Brain Res 1343: 226–35.
- 11. Vogel W et al. (2003) Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells. Haematologica 88(2): 126–33 (FC, ICC)
- 12. Mason D et al. (Eds.). (2002) Leucocyte Typing VII: White cell differentiation antigens. New York: Oxford University Press. (FC)
- 13. Pierelli L et al. (2001) CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymphoma 42(6): 1195–206.
- 14. Azuma H. (2000) Genetic and molecular pathogenesis of hereditary hemorrhagic telangiectasia. J Med Invest 47(3-4): 81–90.
- 15. Bourdeau A et al. (2000) Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 10(7): 279–85.
- 16. Gallione CJ et al. (1998) Mutation and expression analysis of the endoglin gene in hereditary hemorrhagic telangiectasia reveals null alleles. Hum Mutat 11(4): 286–94.
- 17. Altomonte M et al. (1996) Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma. Br J Cancer 74(10): 1586–91.
- 18. Wu X et al. (1995) Cloning and characterization of the murine activin receptor like kinase-1 (ALK-1) homolog. Biochem Biophys Res Commun 216(1): 78–83.
- 19. Bühring HJ et al. (1991) Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. Leukemia 5(10): 841-7.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2020 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, Scientists Helping Scientists, and MesenCult are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. Alexa Fluor® is a registered trademark of Life Technologies Corporation. Antibodies conjugated to Alexa Fluor® are licensed for internal research use only and sale is expressly conditioned on the buyer not using the antibody for manufacturing, performing a service or medical test, or otherwise generating revenue. For use other than research, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.